Who are Baxdrostat/dapagliflozin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Baxdrostat and dapagliflozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/baxdrostat-dapagliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Baxdrostat/dapagliflozin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baxdrostat/dapagliflozin (Baxdrostat/dapagliflozin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aldosterone synthase inhibitor + SGLT2 inhibitor combination. Area: Cardiovascular, Nephrology.

phase 3 Aldosterone synthase inhibitor + SGLT2 inhibitor combination CYP11B2 (aldosterone synthase) and SGLT2 (sodium-glucose cotransporter 2) Cardiovascular, Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Baxdrostat/dapagliflozin (Baxdrostat/dapagliflozin) — AstraZeneca. Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion and reduce sodium reabsorption.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Baxdrostat/dapagliflozin TARGET	Baxdrostat/dapagliflozin	AstraZeneca	phase 3	Aldosterone synthase inhibitor + SGLT2 inhibitor combination	CYP11B2 (aldosterone synthase) and SGLT2 (sodium-glucose cotransporter 2)
Baxdrostat and dapagliflozin	Baxdrostat and dapagliflozin	AstraZeneca	phase 3	Aldosterone synthase inhibitor + SGLT2 inhibitor combination	CYP11B2 (aldosterone synthase) and SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aldosterone synthase inhibitor + SGLT2 inhibitor combination class)

AstraZeneca · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baxdrostat/dapagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/baxdrostat-dapagliflozin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab